Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PIII Stock Forecast 2025-2026
$6.20
Current Price
$1.26B
Market Cap
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to PIII Price Targets
+29.0%
To High Target of $8.00
+29.0%
To Median Target of $8.00
+29.0%
To Low Target of $8.00
PIII Price Momentum
-2.4%
1 Week Change
-21.9%
1 Month Change
-79.8%
1 Year Change
-44.9%
Year-to-Date Change
-81.4%
From 52W High of $33.30
0.0%
From 52W Low of $6.20
📊 TOP ANALYST CALLS
Did PIII Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if P3 Health Partners is one of their latest high-conviction picks.
Latest PIII Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, PIII has a neutral consensus with a median price target of $8.00 (ranging from $8.00 to $8.00). The overall analyst rating is Buy (7.3/10). Currently trading at $6.20, the median forecast implies a 29.0% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PIII Analyst Ratings
1
Buy
2
Hold
0
Sell
PIII Price Target Range
Low
$8.00
Average
$8.00
High
$8.00
Current: $6.20
Latest PIII Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PIII.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | Lake Street | Brooks O'Neil | Buy | Maintains | $20.00 |
| Nov 20, 2024 | TD Cowen | Gary Taylor | Hold | Maintains | $0.25 |
| Apr 1, 2024 | BTIG | David Larsen | Neutral | Downgrade | $0.00 |
| Mar 14, 2024 | Lake Street | Brooks O'Neil | Buy | Maintains | $4.50 |
| Sep 1, 2023 | BTIG | David Larsen | Buy | Initiates | $5.00 |
| Jun 30, 2023 | TD Cowen | Gary Taylor | Market Perform | Initiates | $0.00 |
| Jan 4, 2022 | William Blair | Ryan Daniels | Outperform | Initiates | $0.00 |
P3 Health Partners Inc. (PIII) Competitors
The following stocks are similar to P3 Health Partners based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
P3 Health Partners Inc. (PIII) Financial Data
P3 Health Partners Inc. has a market capitalization of $1.26B with a P/E ratio of -0.1x. The company generates $1.49B in trailing twelve-month revenue with a -9.3% profit margin.
Revenue growth is -3.9% quarter-over-quarter, while maintaining an operating margin of -10.2% and return on equity of -120.4%.
Valuation Metrics
Market Cap
$1.26B
Enterprise Value
$221.20M
P/E Ratio
-0.1x
PEG Ratio
-29.5x
Price/Sales
0.8x
Growth & Margins
Revenue Growth (YoY)
-3.9%
Gross Margin
N/A
Operating Margin
-10.2%
Net Margin
-9.3%
EPS Growth
-3.9%
Financial Health
Cash/Price Ratio
+197.8%
Current Ratio
0.4x
Debt/Equity
151.1x
ROE
-120.4%
ROA
-23.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
P3 Health Partners Inc. (PIII) Business Model
About P3 Health Partners Inc.
What They Do
Transforming primary care in the U.S.
Business Model
The company operates within the Medicare Advantage space, generating revenue by providing high-quality, coordinated care to senior communities. Its business model focuses on integrating clinical services, wellness programs, and technology solutions to enhance patient outcomes and satisfaction while reducing costs associated with hospital admissions.
Additional Information
P3 Health Partners collaborates with healthcare providers to align with value-based care models, utilizing advanced analytics and data-driven insights to improve healthcare efficiency. As demand for patient-centric healthcare rises, the company is positioned as a key player in the evolving healthcare market.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
360
CEO
Dr. Aric Coffman M.D.
Country
United States
IPO Year
2021
Website
p3hp.orgP3 Health Partners Inc. (PIII) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Bears are Losing Control Over P3 Health Partners (PIII), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for P3 Health Partners (PIII), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Jun 12, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
The excerpt does not provide any specific information or news related to financial markets or investments. No summary can be generated.
Why It Matters
The excerpt suggests a potential data collection or marketing strategy, indicating possible changes in company engagement or customer outreach, which could impact investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
P3 Health Partners (PIII) has formed a hammer chart pattern, suggesting support. Upward earnings estimate revisions may indicate a potential trend reversal soon.
Why It Matters
The hammer chart pattern signals potential price support for P3 Health Partners, while rising earnings estimates suggest a possible trend reversal, indicating a favorable buying opportunity.
Source: Zacks Investment Research
Market Sentiment:
Negative
Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)
24 days ago
Quick Summary
P3 Health Partners (PIII) is in oversold territory, suggesting potential for a trend reversal, supported by analysts raising earnings estimates.
Why It Matters
P3 Health Partners (PIII) may be poised for recovery, with oversold conditions and upward revisions in earnings estimates from analysts signaling potential buying opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
P3 Health Partners Inc. (NASDAQ: PIII) will host its Q1 2025 Earnings Conference Call on May 15, 2025, at 4:30 PM ET, featuring key company executives and analysts.
Why It Matters
P3 Health's upcoming earnings call will provide insights into its financial performance and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
P3 Health Partners Inc. (NASDAQ: PIII) reported its Q1 2025 financial results and reaffirmed its 2025 guidance, highlighting its physician-led care model's effectiveness in quality and cost management.
Why It Matters
P3 Health Partners' Q1 results and reaffirmed guidance signal confidence in its growth strategy and operational effectiveness, which could enhance investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
P3 Health Partners Inc. (PIII) reported a quarterly loss of $6.28 per share, worse than the estimated loss of $5, but an improvement from a loss of $8 per share a year earlier.
Why It Matters
P3 Health Partners’ larger-than-expected quarterly loss signals potential operational issues, which may affect investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About PIII Stock
What is P3 Health Partners Inc.'s (PIII) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, P3 Health Partners Inc. (PIII) has a median price target of $8.00. The highest price target is $8.00 and the lowest is $8.00.
Is PIII stock a good investment in 2025?
According to current analyst ratings, PIII has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PIII stock?
Wall Street analysts predict PIII stock could reach $8.00 in the next 12 months. This represents a 29.0% increase from the current price of $6.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is P3 Health Partners Inc.'s business model?
The company operates within the Medicare Advantage space, generating revenue by providing high-quality, coordinated care to senior communities. Its business model focuses on integrating clinical services, wellness programs, and technology solutions to enhance patient outcomes and satisfaction while reducing costs associated with hospital admissions.
What is the highest forecasted price for PIII P3 Health Partners Inc.?
The highest price target for PIII is $8.00 from at , which represents a 29.0% increase from the current price of $6.20.
What is the lowest forecasted price for PIII P3 Health Partners Inc.?
The lowest price target for PIII is $8.00 from at , which represents a 29.0% increase from the current price of $6.20.
What is the overall PIII consensus from analysts for P3 Health Partners Inc.?
The overall analyst consensus for PIII is neutral. Out of 4 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are PIII stock price projections?
Stock price projections, including those for P3 Health Partners Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 9:48 AM UTC